Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Express Scripts Turns To Compounding To Fight High-Priced Off-Patent Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Pharmacy benefit manager's anti-Daraprim effort signals new direction in pricing battles, but the strategy can only be used in limited circumstances.


Related Content

Drug Compounding Can't Be Justified By Price, FDA Says
Building A Foundation: Express Scripts’ Miller On Recent Outcomes-Based Contracts
Eye Of The Pricing Storm: FDA's Woodcock Withstands Gale-Force Rhetoric
“Temporary Compounding” To Mitigate Off-Patent Monopolies
Pricing Policies Should Fit Arc, Not Spike, New PhRMA CEO Says
Compounded Pyrimethamine: 'Personalized Medicine' Or 'Unapproved Drug'?
Compounding For Lower Prices Not PBMs’ New ‘Game Plan,’ Lawmakers Told
Senate's Bipartisan Rx Pricing Probe Seeks Documents Regarding FDA Regs
PhRMA Takes Aim At Valeant In Defense Of Drug Pricing By ‘Innovative’ Firms
Compounding Law: How Many “Outsourcing Facilities” Will Emerge?


Related Companies